Vivos Stock Today

VVOS -  USA Stock  

USD 3.90  0.08  2.01%

Vivos Therapeutics is selling at 3.90 as of the 20th of October 2021; that is -2.01 percent decrease since the beginning of the trading day. The stock's lowest day price was 3.81. Vivos Therapeutics has about a 26 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Vivos Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of November 2019 and ending today, the 20th of October 2021. Click here to learn more.
 Market Performance
3 of 100
  Odds Of Distress
Less than 26
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea . Vivos Therapeutics, Inc. The company has 22.81 M outstanding shares of which 286.2 K shares are at this time shorted by private and institutional investors with about 0.03 trading days to cover. More on Vivos Therapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Vivos Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Vivos Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vivos Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Vivos Therapeutics has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 14.54 M. Net Loss for the year was (20.94 M) with profit before overhead, payroll, taxes, and interest of 10.41 M.
Vivos Therapeutics currently holds about 34.2 M in cash with (11.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.5.
Roughly 22.0% of the company outstanding shares are owned by insiders
Latest headline from www.marketscreener.com: Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution - marketscreener.com
Legal NameVivos Therapeutics
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Vivos Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Vivos Therapeutics (VVOS) is traded on NASDAQ Exchange in USA and employs 133 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 88.51 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vivos Therapeutics's market, we take the total number of its shares issued and multiply it by Vivos Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Vivos Therapeutics conducts business under Healthcare sector and is part of Medical Devices industry. The entity has 22.81 M outstanding shares of which 286.2 K shares are at this time shorted by private and institutional investors with about 0.03 trading days to cover. Vivos Therapeutics currently holds about 34.2 M in cash with (11.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.5.
Check Vivos Therapeutics Probability Of Bankruptcy
Ownership
Vivos Therapeutics maintains a total of 22.81 Million outstanding shares. Vivos Therapeutics maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Vivos Ownership Details

Vivos Stock Price Odds Analysis

What are Vivos Therapeutics' target price odds to finish over the current price? In regard to a normal probability distribution, the odds of Vivos Therapeutics jumping above the current price in 90 days from now is about 57.47%. The Vivos Therapeutics probability density function shows the probability of Vivos Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.1181. This entails Vivos Therapeutics market returns are sensible to returns on the market. As the market goes up or down, Vivos Therapeutics is expected to follow. Additionally, the company has an alpha of 0.1799, implying that it can generate a 0.18 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 3.9HorizonTargetOdds Up 3.9 
42.44%90 days
 3.90 
57.47%
Based on a normal probability distribution, the odds of Vivos Therapeutics to move above the current price in 90 days from now is about 57.47 (This Vivos Therapeutics probability density function shows the probability of Vivos Stock to fall within a particular range of prices over 90 days) .

Vivos Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Vivos Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vivos Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vivos Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares383.9 K1.9 M
Royce Associates LpCommon Shares348 K1.7 M
View Vivos Therapeutics Diagnostics

Vivos Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Vivos Therapeutics market risk premium is the additional return an investor will receive from holding Vivos Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vivos Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Vivos Therapeutics' alpha and beta are two of the key measurements used to evaluate Vivos Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Vivos Stock Against Markets

Picking the right benchmark for Vivos Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Vivos Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Vivos Therapeutics is critical whether you are bullish or bearish towards Vivos Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vivos Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module
Also, please take a look at World Market Map. Note that the Vivos Therapeutics information on this page should be used as a complementary analysis to other Vivos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Vivos Stock analysis

When running Vivos Therapeutics price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
The market value of Vivos Therapeutics is measured differently than its book value, which is the value of Vivos that is recorded on the company's balance sheet. Investors also form their own opinion of Vivos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vivos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vivos Therapeutics' market value can be influenced by many factors that don't directly affect Vivos Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vivos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Vivos Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vivos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.